<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199403</url>
  </required_header>
  <id_info>
    <org_study_id>SPLEEN</org_study_id>
    <nct_id>NCT04199403</nct_id>
  </id_info>
  <brief_title>Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients</brief_title>
  <acronym>SPLEEN</acronym>
  <official_title>Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pr Pierre BUFFET Institut National de la Transfusion Sanguine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pr Sophie CANDON Laboratoire d'immunologie et biothérapies CHU de Rouen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr Edouard TUAILLON Département Bactériologie-Virologie/INSERM U1058 CHU de Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spleen could have been surgically removed for trauma, cancer, auto-immune disease, or to
      perform a diagnosis. Spleen could be non-functional due to radiotherapy or splenic artery
      embolism. These patients are at risks of infectious diseases due to encapsulated bacteria,
      cancer, and thromboembolism disease. The purpose of this study is to assess complications
      occurring in French patients without spleen and to implement new diagnostic tools for
      follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asplenia can be congenital or acquired. Acquired asplenia can be due to diagnostic or
      therapeutic surgery, splenic artery embolization, or radiotherapy. Incidence of
      splenectomized patients was estimated between 10 and 15/100 000 persons in 2003. More recent
      data suggested a decrease in splenectomy due to increase of splenic artery embolization. From
      212 to 2016, about 4000 splenectomy had still been performed.

      Three different risks are known for asplenic patients: infectious, neoplastic, and
      thromboembolic. Prevalence rate of infectious complications in splenectomized patients was
      3.2% with a mortality rate of 1.4%. A US cohort study including 8149 splenectomized veterans
      have shown that the risk of cancer was increased, so did the risk of thromboembolic disease,
      on a 27-year period of follow-up. Pathophysiology of these risks are not well known.

      There are very few tools to assess splenic function: Howell-Jolly bodies in red blood cells,
      scintigraphy. These tools lack sensitivity and are not correlated with complications in
      asplenic patients.

      To better understand how splenic function and how immunity evolves during time in asplenic
      patients, a longitudinal follow-up could be useful. There may be some differences between
      splenectomized patients, those who benefited from splenic artery embolization, and those who
      received radiotherapy. Infectious risk may be different between these three groups.
      Implementing new tools assessing residual splenic function could improve management of these
      patients. A prospective follow-up aims at accurately estimate the incidence rate of
      infectious and non-infectious complications in this population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">January 2040</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Assessment of complication risk factors</measure>
    <time_frame>3 years</time_frame>
    <description>Comparison between splenectomy and other type of asplenia for prevalence of infectious diseases, cancer, and thromboembolism disease</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Asplenia</condition>
  <arm_group>
    <arm_group_label>Single Group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients &gt;18 years with acquired asplenia due to splenectomy, artery embolization, or
        spleen radiotherapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 year-old

          -  With asplenia due to splenectomy, splenic artery embolization or radiotherapy

        Exclusion Criteria:

          -  Genetic asplenia including sick cell disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blandine Rammaert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>C.H.U. de Poitiers</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blandine Rammaert, MD</last_name>
    <phone>+33 5 49 44 44 22</phone>
    <email>blandine.rammaert.paltrie@univ-poitiers.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Corinne Lorrain</last_name>
    <phone>+33 5 49 44 39 30</phone>
    <email>corinne.lorrain@chu-poitiers.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blandine Rammaert, MD</last_name>
      <phone>+33 5 49 44 19 48</phone>
      <email>blandine.rammaert.paltrie@univ-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014 Feb;99(2):392-8. doi: 10.3324/haematol.2013.092460. Epub 2013 Sep 20.</citation>
    <PMID>24056815</PMID>
  </results_reference>
  <results_reference>
    <citation>Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005 Aug;5(8):606-16. Review.</citation>
    <PMID>16056254</PMID>
  </results_reference>
  <results_reference>
    <citation>Aiolfi A, Inaba K, Strumwasser A, Matsushima K, Grabo D, Benjamin E, Lam L, Demetriades D. Splenic artery embolization versus splenectomy: Analysis for early in-hospital infectious complications and outcomes. J Trauma Acute Care Surg. 2017 Sep;83(3):356-360. doi: 10.1097/TA.0000000000001550.</citation>
    <PMID>28459796</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spleen</keyword>
  <keyword>asplenic patients</keyword>
  <keyword>splenectomy</keyword>
  <keyword>asplenia</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

